What Became of Eligo Bioscience's EIC Accelerator CRISPR Pill

Eligo Bioscience set out to do something no one had done: send a CRISPR gene-cutting enzyme into the gut of a sick child, find the bacteria making a lethal toxin, cut the toxin gene, and leave every other microbe untouched. The European Commission selected the company in the EIC SME Instrument Phase 2 cut-off of 9 January 2019 and awarded it €2,763,775 towards a €3,948,250 project called SPELITEC, according to CORDIS. Eligo appears as the French winner of that round in the European Commission's published list of selected companies, with the proposal acronym SPELITEC and its own website. It was the only beneficiary of the project; no partner company shares the grant.

The project's goal was explicit and testable. Its summary on CORDIS says SPELITEC would "finalise preclinical and initiate clinical studies" for EB003, an oral drug against Shiga toxin-producing Escherichia coli (STEC), the infection that gives small children bloody diarrhoea and, in a minority of cases, haemolytic uraemic syndrome and kidney failure. Antibiotics are contraindicated because they can trigger the bacteria to release more toxin. Seven and a half years after the award, the preclinical half of that sentence is done and published. The clinical half has not happened.

Where Eligo Stands Now

The company is active and still in Paris. The French business register, queried through the government's recherche-entreprises service, shows the entity in good standing with an active head office at 111 Avenue de France and no insolvency entry. North Data's publication history records a capital increase to €173,296 filed in June 2026 and board filings as recent as September 2026, so the company is both funded and reporting.

What it is not is a company still led by EB003. Its December 2023 Series B of $30 million, led by Sanofi Ventures with Bpifrance, Khosla Ventures and Seventure Partners, was earmarked in the company's own announcement for "accelerating the development of Eligo's flagship program, EB005, which targets moderate to severe acne vulgaris", and for pre-IND and IND work towards a Phase 1b/2a trial in that indication. EB003, the drug the EIC paid for, is not mentioned in that release. In May 2025 the company took a further $5 million from the French state under the France 2030 programme, again for the topical acne vector and a broader immuno-dermatology pipeline. Its current platform page presents three technologies, SSAM, GEM and FAME, and names no lead clinical candidate at all.

The Technology: A Phage Shell With a Gene Cutter Inside

Eligo's devices are not phages in the usual sense. The company engineers the protein shell of a bacteriophage, strips out the viral genome and fills the capsid with a non-replicating DNA payload. The shell's natural host range decides which bacteria it enters; the payload decides what happens next. In the sequence-specific antimicrobial version used for EB003, the payload encodes a CRISPR nuclease and a guide RNA aimed at the stx genes that encode Shiga toxin. Bacteria carrying the sequence are cut and die. Bacteria without it are left alone, which is the whole point: conventional antibiotics flatten the gut flora and, in STEC specifically, can induce the prophages that carry stx and so increase toxin release.

The peer-reviewed description arrived on 27 May 2026, when Science Translational Medicine published "Treatment of Shiga toxin-producing E. coli infection by CRISPR-Cas-targeted cleavage of the Shiga toxin gene in animal models" by Galtier and 28 co-authors, nearly all at Eligo, with two also at the Institut Pasteur. The paper reports a Cas12 nuclease cleaving more than 99% of stx variants in O157 clinical isolates, an engineered capsid that delivers a non-replicative payload to E. coli O157, a reduction of bacterial burden in a mouse colonisation model, and in infant rabbits symptom mitigation, abrogated toxin-mediated damage and faster epithelial repair. The authors state that the findings "support further clinical development of EB003". The subject of the paper is animals.

The adjacent capability is better established. In July 2024 the same group published base editing of bacteria inside the mouse gut in Nature, reporting a median editing efficiency of 93% of the target population from a single oral dose and edited bacteria persisting for at least 42 days. That paper is the technical basis of the acne programme, where the aim is not to kill a bacterium but to switch off a gene in Cutibacterium acnes or make skin commensals produce a biologic locally.

What SPELITEC Promised, and What CORDIS Shows

SPELITEC ran from 1 April 2019 to 31 March 2022 under the SME instrument topic of Horizon 2020, with the grant agreement signed on 14 June 2019. CORDIS lists four objectives: move EB003 manufacturing from laboratory to industrial scale, confirm efficacy in preclinical models, confirm safety in regulatory toxicology, and "obtain validation from regulatory agencies to perform first clinical trials in humans". The final periodic report, published in November 2022, is candid about where the project stopped. Manufacturing was transferred to a contract developer at 100 litres in GMP-like conditions, which the company calls a first for this type of product. The active substance killed more than 99.99% of targeted bacteria across a collection of over 100 clinical STEC isolates and was active on more than 95% of them. Mouse decolonisation showed more than 99.9% clearance six hours after an oral dose, and infant rabbit data showed symptom mitigation. Two GLP-like toxicology studies were done.

On the fourth objective the report says only that "interactions with regulatory agencies have helped us assess the regulatory requirements for EB003's entry in clinics" and lists as a key next step "obtaining the authorization from regulatory agencies to perform clinical studies in humans". That is the objective restated as future work. The project closed without the clinical studies its own description said it would initiate, and without the regulatory authorisation needed to start them.

1. Industrial-scale manufacturing of EB003Delivered100L GMP-like batch at a contract developer, per the CORDIS report.
2. Preclinical efficacy in vitro and in vivoDeliveredMouse and infant rabbit data, peer reviewed in Science Translational Medicine in May 2026.
3. Safety in regulatory toxicology modelsDeliveredTwo GLP-like studies plus human cell work, per CORDIS.
4. Regulatory validation to start trials in humansNot achievedListed as a next step in the final report; no authorisation announced since.
5. Initiate clinical studies (Q2 2022, per the company)Not achievedNo EB003 study is listed on ClinicalTrials.gov and none is announced on the company's news page.
6. Out-license EB003 to an established pharma companyUnverifiedNo licensing deal for EB003 has been announced; the 2021 GSK deal covers EB005.

Credit where it is due: a grant funds development, not approval, and the regulatory paperwork around a first-in-class living-derived gene therapy for infants is not a formality. Eligo also banked two designations that only a serious preclinical file earns. The European Medicines Agency granted EB003 orphan drug designation before June 2021, and on 11 October 2022 the FDA granted both orphan drug and rare paediatric disease designation for EB003 in the prevention of haemolytic uraemic syndrome, according to the company's announcement. That release described EB003 as "IND-enabled with a robust manufacturing process at the 100L-scale, full preclinical package and a clear regulatory path-to-clinic". Four years on, the path has not been walked.

What Has Happened Since the Award

Measured by capital and reputation, a great deal. Eligo raised $20 million in a Series A led by Khosla Ventures and Seventure Partners in September 2017, before the grant, according to TechCrunch and tech.eu, which also records a €2 million award from France's Worldwide Innovation Challenge. In June 2020, three months into the EIC project's second year, CARB-X awarded $1.82 million, with up to $7.05 million on milestones, for EB004 against drug-resistant E. coli and Klebsiella pneumoniae in transplant patients. In January 2021 GSK signed a research and option agreement on the acne candidate EB005 that BioSpace valued at up to $224 million including milestones and royalties; the upfront sum is not public, and no exercise of GSK's option has been announced. Then came the Series B, later expanded to $35 million per the company's France 2030 release, and the appointment of Bobby Gaspar, formerly chief executive of Orchard Therapeutics, as board chair in October 2024, alongside new investors including VIVES Partners, which the release says is supported by the EU's InvestEU Fund.

Measured by filed accounts, the picture is thinner, because France publishes little for free. The government register's financial extract shows a 2024 net loss of €4,592,226 with revenue recorded as zero, and Societe.com adds a 2022 net loss of €6,596,000 and a staff band of 20 to 49. North Data's free view confirms balance sheets filed from 2016 to 2024 but keeps the figures behind a subscription, so a full loss series could not be verified. The company's own team page lists 33 named staff. No revenue has been reported in any public source, which is what a preclinical biotech looks like.

Why Europe Should Care

STEC is a European public health problem with a European history: the 2011 outbreak in Germany killed more than 50 people, a fact the CORDIS report itself cites. More broadly, the drug sits inside the EU's antimicrobial resistance policy. The Commission's action on antimicrobial resistance and the Council recommendation adopted on 13 June 2023 push both for prudent antibiotic use and, in the recommendation's words, to "foster research & development, and incentives for innovation and access to antimicrobials and other AMR medical countermeasures". A drug that kills one pathogenic strain while sparing the microbiota is close to the ideal that policy describes. Keeping a platform of this kind in a European company, rather than licensing it out early, is the strategic-autonomy version of the same point, and the one place the record is least reassuring: the first big pharma deal Eligo signed was with GSK, on the dermatology asset, not the one European taxpayers funded.

The Verdict

Eligo Bioscience has not been asked for comment for this article. It is based entirely on public records, company statements, peer-reviewed papers and EU project data, linked throughout.